Maduck Sean's Form 4 filing
Corcept Therapeutics Inc (CORT) · filed Sep 3, 2026
- Accession no.
- 0001193125-26-382474
- Filed
- Sep 3, 2026, 9:16 PM ET
- Trade date
- Sep 1-2, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 7 non-derivative transactions and 1 derivative transaction. Open-market sales total $2.86M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Maduck SeanCIK 0001698310 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | Common Stock | MOption exerciseAcquired | +25,000 | $8.27 | +$206,750 | 34,755 | Direct | |
| Sep 1, 2026 | Common Stock | SSaleDisposed | −11,730 | $113.94F3 | −$1,336,458.72 | 23,025 | Direct | |
| Sep 1, 2026 | Common Stock | SSaleDisposed | −10,989 | $114.71F4 | −$1,260,567.97 | 12,036 | Direct | |
| Sep 1, 2026 | Common Stock | SSaleDisposed | −2,281 | $115.61F5 | −$263,710.52 | 9,755 | Direct | |
| Sep 1, 2026 | Common Stock | AGrant or awardAcquired | +150 | $113.38F7 | +$17,007 | 9,905 | Direct | |
| Sep 1, 2026 | Common Stock | AGrant or awardAcquired | +150 | $0.00 | $0 | 10,055 | Direct | |
| Sep 2, 2026 | Common Stock | FTax withholdingDisposed | −117 | $113.38F10 | −$13,265.46 | 9,938 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | Common Stock | MOption exerciseDisposed | −25,000 | $0.00 | $0 | 66,986 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $113.36 to $114.34 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.
- F4
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $114.365 to $115.295 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.
- F5
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.37 to $115.82 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.
- F7
In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
Referenced by the price of 1 transaction in Table I.
- F10
The closing price on September 1, 2026 was used to calculate the withholding obligation.
Referenced by the price of 1 transaction in Table I.
Remarks
President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission.